X

Trial Profile

A Cancer Research UK Phase I Trial of AZD3965, a Monocarboxylate Transporter 1 Inhibitor (MCT1) in Patients With Advanced Cancer

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 04 Oct 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs AZD 3965 (Primary)
Indications Burkitt's lymphoma; Diffuse large B cell lymphoma; Lymphoma; Solid tumours
Focus Adverse reactions; First in man

Most Recent Events

18 Jan 2023 Results (n=40) assessing safety and pharmacokinetics of the dose-escalation part of AZD3965 in advanced cancer, published in the Clinical Cancer Research.
16 Aug 2021 Status changed from active, no longer recruiting to completed.
08 Jun 2021 Results (n=11) of patients with relapsed/refractory DLBCL and BL expansion cohort presented at the 57th Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com